Merck & CompanyvsProtagonist Therapeutics

MRK and PTGX stock compared: price, dividend, valuation and results, from SEC filings.

MRK

Merck & Company, Inc.

$132.81

Value $328B

-3.61%
MRK's page

PTGX

Protagonist Therapeutics, Inc.

$124.02

Value $7.9B

-2.47%
PTGX's page

Merck & Company (MRK) has a market value of $328B and Protagonist Therapeutics (PTGX) $7.9B. Over the last year, with dividends, MRK moved +41.8% and PTGX +47.0%. The P/E is 133.9 for MRK and 23.1 for PTGX. Dividend yield: MRK 2.56%, PTGX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MRK$328B

    PTGX$7.9B

    MRK is 41 times PTGX

  • Revenue, 12 months

    MRK$67.4B

    PTGX$552M

    MRK is 122 times PTGX

  • Net income, 12 months

    MRK$2.5B

    PTGX$342M

    MRK is 7.2 times PTGX

  • Operating margin

    MRK–

    PTGX58.6%

  • ROIC

    MRK3.9%

    PTGX33.2%

    29.3 points apart

  • P/E

    MRK133.9

    PTGX23.1

    MRK is 5.8 times PTGX

  • Dividend yield

    MRK2.6%

    PTGX0.0%

    2.6 points apart

  • 5-year return

    MRK+86.3%

    PTGX+240.6%

    154.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MRK+86.3%

PTGX+240.6%

020040020222023202420252026
Returns by period
PeriodMRKWith dividendsPTGXWith dividends
1 year since November 18, 2025+41.8%Price +37.7%+47.0%Price +47.0%
3 years since November 17, 2023+43.1%+12.7% a yearPrice +30.5%+637.8%+94.7% a yearPrice +637.8%
5 years since November 18, 2021+86.3%+13.2% a yearPrice +59.9%+240.6%+27.8% a yearPrice +240.6%
10 years since November 21, 2016+203.1%+11.7% a yearPrice +123.4%+392.1%+17.3% a yearPrice +392.1%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MRKMerck & CompanyPTGXProtagonist Therapeutics

Valuation

MRKPTGX
Valuation
Price$132.81$124.02
Market value$328B$7.9B
Enterprise value (EV)$372B$7.1B
P/E133.923.1
P/E, 5-year median14.8–
P/B7.37.3
EV/EBIT78.222.0
Free cash flow yield4.5%1.4%

Results and growth

MRKPTGX
Results and growth
Revenue, 12 months$67.4B$552M
Net income, 12 months$2.5B$342M
Free cash flow, 12 months$14.7B$109M
Earnings per share, 12 months$0.98$5.36
Revenue growth, year on year1.3%-89.4%
Revenue growth a year, past+9.4%over 5 years+10.0%over 5 years
EPS growth a year, past+21.2%over 5 years–

Margins and returns on capital

MRKPTGX
Margins and returns on capital
Gross margin71.8%–
Operating margin–58.6%
Net margin3.6%62.0%
ROIC3.9%33.2%
ROE5.2%44.5%

Balance sheet

MRKPTGX
Balance sheet
Cash$9.7B$800M
Total debt$53.8B$8.6M
Net debt / EBITDA5.7-2.5
Interest cover2.4×–

Dividends and buybacks

MRKPTGX
Dividends and buybacks
Dividend yield2.6%–
Dividend per share, 12 months$3.40–
Dividend growth a year, past+5.8%over 5 years–
Buyback yield1.6%–
Shareholder yield4.1%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MRK or PTGX

Didn't find what you were looking for?

Ask us
Which is bigger, Merck & Company or Protagonist Therapeutics?

By market value, Merck & Company ($328B) is about 41.5 times Protagonist Therapeutics ($7.9B), at today's prices.

How did MRK and PTGX stock do over the last 10 years?

Since November 21, 2016, MRK's price moved +123.4% and PTGX's +392.1%. With dividends: MRK +203.1% (+11.7% a year), PTGX +392.1% (+17.3% a year). Past returns do not predict future ones.

Which pays the higher dividend, MRK or PTGX?

The dividend yield at today's price is 2.56% for Merck & Company and none for Protagonist Therapeutics. Over the last twelve months they paid $3.40 and – per share.

What is the P/E of MRK and PTGX?

At today's price, the P/E is 133.9 for MRK and 23.1 for PTGX. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Merck & Company or Protagonist Therapeutics?

Over the last twelve months, the net margin was 3.6% for Merck & Company and 62.0% for Protagonist Therapeutics, and the operating margin – and 58.6%. Revenue was $67.4B and $552M.

Which is the better investment, Merck & Company or Protagonist Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.